Meeting
2022 ASCO Annual Meeting
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
Authors
Javier E. Oesterheld
Levine Children's Hospital at Carolinas Medical Center, Charlotte, NC
Javier E. Oesterheld , Genevieve Bergendahl , Donald A. Berry , Elizabeth Lorenzi , Thomas Clinch , Jacqueline M. Kraveka , William Ferguson , Valerie I. Brown , Don Eslin , Derek Hanson , Virginia Lynn Harrod , Michael Isakoff , Deanna Mitchell , Randal Wada , Peter E. Zage , Giselle Linda Saulnier Sholler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02395666, NCT00026312
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10010)
DOI
10.1200/JCO.2022.40.16_suppl.10010
Abstract #
10010
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
First Author: Scott Moerdler
Poster
2021 ASCO Annual Meeting
Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.
First Author: Caileigh Pudela
Poster
2018 ASCO Annual Meeting
The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.
First Author: Keith Holmes
Poster
2016 ASCO Annual Meeting
Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.
First Author: Maya Suzuki